CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the formation of the POZEN Digital Advisory Board. POZEN has assembled an esteemed group of digital thought-leaders both in and outside of healthcare to help progress the Company's vision for revolutionizing the traditional pharmaceutical commercial model. Through both the Company’s unique clinical development and marketing approach, POZEN aims to bring lifesaving drugs to market more affordably than current models allow. The Digital Advisory Board will work alongside the Company as it prepares to launch and market its first products – including PA32540, being investigated for the secondary prevention of cardiovascular and cerebrovascular disease – and will advise POZEN on the use of digital technology to more effectively and efficiently engage and communicate with customers.
